PART I Overview We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We believe that our array of technology platforms uniquely positions us among other biotechnology c...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001356090-26-000009 | EDGAR | 81K words |
| 2025-03-19 | 2024-12-31 | 0001356090-25-000007 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001356090-24-000007 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0001356090-23-000004 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001356090-22-000002 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001356090-21-000003 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001628280-20-002699 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001356090-19-000004 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001356090-18-000002 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001356090-17-000003 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001356090-26-000030 | EDGAR | — |
| 2025-11-13 | 2025-09-30 | 0001356090-25-000034 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001356090-25-000024 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001356090-25-000019 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001356090-24-000026 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001356090-24-000017 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001356090-24-000010 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001356090-23-000017 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001356090-23-000013 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001356090-23-000009 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001356090-22-000013 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001356090-22-000009 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0000950103-26-011876 | EDGAR | — |
| 2026-03-25 | 0000950103-26-004648 | EDGAR | 3K words |
| 2025-11-13 | 0000950103-25-014683 | EDGAR | — |
| 2025-09-17 | 0000950103-25-011775 | EDGAR | — |
| 2025-09-03 | 0001104659-25-086669 | EDGAR | — |
| 2025-08-18 | 0000950103-25-010408 | EDGAR | — |
| 2025-08-18 | 0001104659-25-079497 | EDGAR | — |
| 2025-06-30 | 0000950103-25-008124 | EDGAR | — |
| 2025-05-14 | 0000950103-25-006004 | EDGAR | — |
| 2025-03-19 | 0000950103-25-003637 | EDGAR | — |
229 total filings indexed. 197 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001356090 |
| Ticker | PGEN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | VA |
| Website | http://www.precigen.com |
| Listed | 2013-08-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PGEN (~200 tokens, structured JSON with cryptographic provenance)